Skip to main content

Table 1 Overview of the OAIs, excipients and packaging used in the compounded formulations

From: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

OAIs Supplier
 L-arginine Fagron, Waregem, Belgium
 L-carnitine Fagron, Waregem, Belgium
 Chenodesoxycholic acid BOC Sciences Creative Dynamics, Shirley, United States
 Primaquine phosphate BOC Sciences Creative Dynamics, Shirley, United States
 Pyridoxal phosphate Inresa, Bartenheim, France
 Sodium benzoate Fagron, Waregem, Belgium
 Sodium perchloratea Merck, Darmstadt, Germany
 Sodium phenylbutyrate Fyrklovern Scandinavia AB, Mönsteras, Sweden
Excipients Supplier
Aurantii amari epicarp et mesocarp tinctura Conforma, Destelbergen, Belgium
Sirupus simplex Conforma, Destelbergen, Belgium
 Methyl paraben Fagron, Waregem, Belgium
 Propyl paraben Fagron, Waregem, Belgium
 Mannitol Fagron, Waregem, Belgium
 Colloidal silicon dioxide Fagron, Waregem, Belgium
Packaging Supplier
 Hard gelatine capsules Capsugel, Bornem, Belgium
 Glass bottles 100 ml Aca Pharma, Nazareth, Belgium
 Plastic opaque cups Aca Pharma, Nazareth, Belgium
  1. aSodium perchlorate is not an OAI but was included in the study as an unlicensed molecule regularly compounded by hospital pharmacists for extemporaneous use